Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Jalyn Prostate Cancer Side Effects Lawsuit

Jalyn Prostate Cancer, Male Breast Cancer Side Effects Lawsuit

Jalyn (Dutasteride/Tamsulosin) Side Effects: Increased Risk of High-Grade Prostate Cancer | Male Breast Cancer Risk by use of 5-Alpha Reductase Inhibitor (5-ARIs) drug class

FDA Says Prostate Drugs Can Cause High-Grade Prostate Cancer

Jalyn (dutasteride/tamsulosin) may increase High-Grade Prostate Cancer and Male Breast Cancer Risk

Jalyn, a drug used to treat enlarged prostate, may be associated with an increased risk of high-grade prostate cancer, an especially aggressive form of the disease. Jalyn contains a combination of dutasteride and tamsulosin, dutasteride is a type of drug known as a 5-alpha reductase inhibitors, or 5-ARIs.

In June 2011, the U.S. Food & Drug Administration (FDA) ordered the makers of 5-ARIs, including Jalyn, to add information about the high-grade prostate cancer risk to the "Warnings and Precautions" sections of the drugs' labels. In August 2011, regulators in Canada announced that the labels of another 5-alpha reductase inhibitor product (finasteride) sold there would be updated to include information regarding their possible association with male breast cancer.

According to Health Canada, male breast cancer has been reported in a small number of patients worldwide with both the 1 mg and 5 mg formulations of finasteride, though most have been associated with the 5mg formulation. Health Canada has advised that men taking finasteride contact their doctors should they experience breast enlargement, breast lumps, pain or tenderness, nipple discharge, or any other changes while taking the drug.

If you or a loved one were diagnosed with high-grade prostate cancer and have been recently diagnosed with male breast cancer while taking jalyn or any other 5-alpha reductase inhibitor class of drug, you may be entitled to compensation.

Parker Waichman LLP urges you to contact our Jalyn lawyers today for a free lawsuit evaluation.

Jalyn (dutasteride/tamsulosin) 5-alpha reductase inhibitors (5-ARIs), Prostate and Male Breast Cancer Risk

Jalyn (dutasteride/tamsulosin) FDA warning was based on two studies indicating men who took Jalyn and any of the other 5-ARI class of drugs were more likely to develop aggressive prostate tumors compared to men on a placebo.

One of those trials, Reduction by Dutasteride of Prostate Cancer Events (REDUCE), compared dutasteride with placebo, and followed more than 8,000 men aged 50-79 for four years. While men on dutasteride had a 23% overall lower risk of being diagnosed with biopsy detectable prostate cancer when compared to men on placebo due to a reduction in low-risk tumors.

By contrast, there was an increased incidence of high-grade prostate cancer with dutasteride versus placebo (1% versus 0.5%, respectively). The maker of Jalyn, GlaxoSmithKline, hade used the REDUCE trial in an attempt to persuade the FDA to expand the drug's use too include prostate cancer prevention

The FDA rejected the request and mandated the new prostate cancer warning for Jalyn and other 5-ARIs.

Jalyn (dutasteride/tamsulosin) Users, High-Grade Prostate Cancer, Male Breast Cancer Victims - Legal Help

If you or a loved one took Jalyn and were diagnosed with high-grade prostate cancer or male breast cancer, you may have valuable legal rights. For a free lawsuit evaluation with one of our Jalyn lawyers, please fill out our online form or call 1-800-YOURLAWYER (1-800-968-7529) today.


5-ARIs Get New Warnings for High-Grade Prostate Cancer in Canada

Mar 21, 2012 | Parker Waichman LLP
Health Canada has announced new warnings for 5-alpha reductase inhibitors, or 5-ARIs, regarding there association with an aggressive form of prostate cancer.  The new warnings will apply to Proscar (finasteride 5mg), Propecia (finasteride 1mg), Avodart (dutasteride) and Jalyn (dutasteride and tamsulosin). Proscar, Avodart and Jalyn are all used to treat enlarged prostate, while Propecia is used to treat male pattern hair loss. According to Health Canada, the new safety information is...

Public Citizen Issues "Do Not Use" Recommendation for Avodart, Proscar

Oct 12, 2011 | Parker Waichman LLP
A leading consumer group is recommending that men with enlarged prostate consider alternatives to the drugs Avodart (dutasteride)  and Proscar (finasteride).   In its latest issue of "Worst Pills, Best Pills", Public Citizen maintains that medications from the alpha-blocker family are safer treatments for this condition. Avodart and Proscar are both 5-alpha reductase inhibitors, or 5-ARIs.  Other drugs in  this class include an  enlarged prostate treatment called...

Propecia, Other 5-ARIs Pose Risk of Erectile Dysfunction

Aug 22, 2011 | Parker Waichman LLP
Propecia and other drugs known as 5-alpha reductase inhibitors (5-ARIs) have been linked to erectile dysfunction, and other sexual problems in men.  Now research is showing that erectile dysfunction associated with Propecia and similar drugs can sometimes be irreversible.Propecia (finasteride 1 mg) is used to treat male pattern baldness.  Other 5-ARIs such as Proscar (finasteride 5 mg), Avodart (dutasteride) and Jalyn (dutasteride and tamsulosin) are used to treat an enlarged...

More Jalyn News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo